Compositions and methods for detecting TLR3
AssigneeInnate Pharma
InventorsKarine Chemin, Laurent Gauthier, Yannis Morel, Carine Paturel, Agnes Tisserant
Life of this patent
Estimating the term…
Abstract
The present invention relates to antibodies, antibody fragments, and derivatives thereof that specifically bind to TLR3 cell receptors present on the surface of cells. The invention also relates to hybridomas producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same; methods of using the antibodies to detect TLR3 levels on the surface of cells, and the use of such antibodies and compositions for diagnostic or therapeutic purposes in subjects.
Claims14
A monoclonal antibody that specifically binds a human toll like receptor 3, (TLR3) polypeptide, wherein said antibody comprises the light chain variable region sequence of SEQ ID NO:3 and the heavy chain variable region sequence of SEQ ID NO:4, and wherein said antibody is designated as 40F9.
An isolated monoclonal antibody comprising:
- a) variable light chain region CDRs:
- KSSQSLLDSDGKTYLN (SEQ ID NO:5;
- CDR1);
- LVSKLDS (SEQ ID NO:6;
- CDR2);
- and WQGIHLPYT (SEQ ID NO:7;
- CDR3) and variable heavy chain region CDRs:
- YTFTNYGMN (SEQ ID NO:8;
- CDR1);
- NANTGEPTYAEEFKG (SEQ ID NO:9;
- CDR2);
- and DYDY (SEQ ID NO:10;
- CDR3);
- or
- b) variable light chain region CDRs:
- KSSQSLLDSDGKTYLN (SEQ ID NO:5;
- CDR1);
- LVSKLDS (SEQ ID NO:6;
- CDR2);
- and WQGIHLPYT (SEQ ID NO:7;
- CDR3) and variable heavy chain region CDRs:
- KASGYTFTNYGMN (SEQ ID NO:11;
- CDR1);
- NANTGEPTYAEEFKG (SEQ ID NO:9;
- CDR2);
- and DYDY (SEQ ID NO:10;
- CDR3).
Dependencies are inferred from the claim text.